Berberine ameliorates intestinal mucosal barrier dysfunction in nonalcoholic fatty liver disease (NAFLD) rats

被引:10
|
作者
Wang, Yuzhen [1 ]
Cui, Suxian [2 ]
Zheng, Jimin [1 ]
Li, Yueqin [1 ]
Li, Pingping [1 ]
Hou, Hongtao [1 ]
机构
[1] Hebei Gen Hosp, Dept Gastroenterol, Shijiazhuang 050051, Hebei, Peoples R China
[2] Hebei Med Univ, Dept Gastroenterol, Shijiazhuang 050017, Hebei, Peoples R China
关键词
Nonalcoholic fatty liver disease; Berberine; Intestinal mucosal barrier; ENDOTOXEMIA; DIET; NOD1;
D O I
10.1016/j.jksus.2020.03.019
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Objective: To study the protective role of berberine (BBR) against nonalcoholic fatty liver disease (NAFLD) on intestinal barrier via investigating its effect on intestinal permeability and intestinal innate immune system in a rat model. Method: Sprague-Dawley rats were randomly divided into three groups: control rats (group N), high-fat diet (HFD) model rats (group M) and BBR-treated rats (group B). Rats in group M and group B were fed with HFD for 12 weeks to induce NAFLD. Rats in group B were then received 4 weeks of BBR administration with continuous HFD feeding. Samples were collected at 16th week. Results: HFD feeding increased the body weight of rats and caused liver steatosis as indicated by hematoxylin & eosin (H&E) staining. Analysis of serum parameters showed that alanine aminotransferase (ALT), aspartate aminotransferase (AST), total cholesterol (TC), triglyceride (TG), endotoxin, interleukin-1 beta (IL-1 beta), interleukin-18 (IL-18), and tumor necrosis factor-alpha (TNF-alpha) were significantly higher in group M as compared group N. These results confirmed the successful establishment of NAFLD in rats. With 4 weeks of BBR administration, body weight of group B decreased significantly as compared with group M. Serum levels of ALT, AST, TC, TG, endotoxin, IL-1 beta, IL-18 and TNF-alpha reduced significantly and hepatocyte steatosis ameliorated. RT-PCR and Western blot analysis showed that BBR reduced the elevated mRNA and protein expressions of innate immune response elements NOD1, NOD2 and NLRP3 that were caused by HFD. BBR also antagonized the effect of NAFLD on Caspase-1 and Claudin-4 protein expressions. Conclusions: BBR alleviates endotoxemia, reduces serum lipids, increases liver function, reduces systemic inflammation and diminishes liver inflammation and steatosis in NAFLD rats. The protective effect of BBR against NALFD is achieved through ameliorating intestinal mucosal barrier dysfunction partly by improving permeability of intestinal mucosa and modulating intestinal innate immune components. (C) 2020 The Authors. Published by Elsevier B.V. on behalf of King Saud University.
引用
收藏
页码:2534 / 2539
页数:6
相关论文
共 50 条
  • [21] Intestinal Barrier Dysfunction in Fatty Liver Disease: Roles of Microbiota, Mucosal Immune System, and Bile Acids
    Gupta, Biki
    Rai, Ravi
    Oertel, Michael
    Raeman, Reben
    SEMINARS IN LIVER DISEASE, 2022, 42 (02) : 122 - 137
  • [22] EARLY CARDIAC DYSFUNCTION IN BIOPSY-PROVEN NONALCOHOLIC FATTY LIVER DISEASE (NAFLD)
    Johnson, Peter C.
    Cochet, Anthony A.
    Gore, Rosco S.
    Harrison, Stephen A.
    Magulick, John P.
    Aden, James K.
    Paredes, Angelo H.
    GASTROENTEROLOGY, 2018, 154 (06) : S1174 - S1174
  • [23] Die nichtalkoholische Fettlebererkrankung (NAFLD)Nonalcoholic fatty liver disease (NAFLD)
    S. Zeuzem
    C. Trautwein
    Der Gastroenterologe, 2020, 15 (2): : 77 - 77
  • [24] Berberine Ameliorates Intestinal Mucosal Barrier Damage Induced by Peritoneal Air Exposure
    Tan, Shanjun
    Yu, Wenkui
    Lin, Zhiliang
    Chen, Qiyi
    Shi, Jialiang
    Dong, Yi
    Duan, Kaipeng
    Bai, Xiaowu
    Xu, Lin
    Yu, Zhen
    Li, Jieshou
    Li, Ning
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2015, 38 (01) : 122 - 126
  • [25] Noninvasive Diagnostics in Nonalcoholic Fatty Liver Disease (NAFLD)
    Stauber R.
    Journal für Gastroenterologische und Hepatologische Erkrankungen, 2019, 17 (3) : 75 - 81
  • [26] An endocrine perspective of nonalcoholic fatty liver disease (NAFLD)
    Lomonaco, Romina
    Chen, Janet
    Cusi, Kenneth
    THERAPEUTIC ADVANCES IN ENDOCRINOLOGY AND METABOLISM, 2011, 2 (05) : 211 - 225
  • [27] Developmental Origins of Nonalcoholic Fatty Liver Disease (NAFLD)
    Itoh, Hiroaki
    Kanayama, Naohiro
    DEVELOPMENTAL ORIGINS OF HEALTH AND DISEASE (DOHAD): FROM BIOLOGICAL BASIS TO CLINICAL SIGNIFICANCE, 2018, 1012 : 29 - 39
  • [28] Vitamin E and nonalcoholic fatty liver disease (NAFLD)
    Thakur, Varsha
    Ulatowski, Lynn
    Parker, Robert
    Zhang, Renliang
    Liu, Xiuli
    Manor, Danny
    FASEB JOURNAL, 2013, 27
  • [29] Antibiotics attenuate diet-induced nonalcoholic fatty liver disease without altering intestinal barrier dysfunction
    Brandt, Annette
    Csarmann, Katja
    Hernandez-Arriaga, Angelica
    Baumann, Anja
    Staltner, Raphaela
    Halilbasic, Emina
    Trauner, Michael
    Camarinha-Silva, Amelia
    Bergheim, Ina
    JOURNAL OF NUTRITIONAL BIOCHEMISTRY, 2024, 123
  • [30] Nutritional Management of Nonalcoholic fatty liver disease (NAFLD)
    Boudaoud, Amel Ait
    Rives-Lange, Claire
    Perregaux, Jean Francois
    Radu, Alina
    Messager-Josipowicz, Diane
    Barsamian, Charles
    Carette, Claire
    Czernichow, Sebastien
    PRESSE MEDICALE, 2019, 48 (12): : 1496 - 1501